ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells $213,474.04 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 1,373 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,262,119.64. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Vivek Jain also recently made the following trade(s):

• On Monday, December 2nd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $162.91, for a total transaction of $1,954,920.00.
• On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $171.84, for a total transaction of $2,062,080.00.

ICU Medical Price Performance

Shares of ICUI traded up $2.81 during midday trading on Thursday, hitting $157.98. 208,164 shares of the company traded hands, compared to its average volume of 269,089. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -34.57 and a beta of 0.62. ICU Medical, Inc. has a 52 week low of $86.80 and a 52 week high of $196.26. The firm has a 50 day moving average of $164.91 and a 200-day moving average of $155.49.

Analysts Set New Price Targets

A number of research firms recently issued reports on ICUI. Raymond James boosted their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. Finally, KeyCorp lifted their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and a consensus price target of $199.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ICUI. Principal Financial Group Inc. raised its position in ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares during the period. Franklin Resources Inc. raised its stake in shares of ICU Medical by 99.3% during the 3rd quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock worth $2,111,000 after acquiring an additional 5,834 shares in the last quarter. Coldstream Capital Management Inc. acquired a new stake in ICU Medical in the 3rd quarter worth approximately $227,000. Geode Capital Management LLC increased its holdings in ICU Medical by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after buying an additional 48,106 shares during the period. Finally, Barclays PLC lifted its holdings in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock valued at $10,790,000 after acquiring an additional 8,010 shares during the period. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.